VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 7, 2026
Stock Comparison
Lifco AB (publ) vs Novartis AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Lifco AB (publ)
LIFCO-B · Nasdaq Stockholm
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Lifco AB (publ)'s moat claims, evidence, and risks.
View LIFCO-B analysisNovartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisComparison highlights
- Moat score gap: Novartis AG leads (65 / 100 vs 58 / 100 for Lifco AB (publ)).
- Segment focus: Lifco AB (publ) has 3 segments (51.2% in Systems Solutions); Novartis AG has 5 segments (29.3% in Oncology).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Lifco AB (publ) has 8 moat types across 2 domains; Novartis AG has 4 across 3.
Primary market context
Lifco AB (publ)
Systems Solutions
Niche B2B systems solutions (contract manufacturing, environmental technology, infrastructure products, special products, transportation products)
Primarily Europe; global customers where applicable
B2B OEMs and industrial customers
Niche manufacturer and systems solution provider
51.2%
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
29.3%
Side-by-side metrics
Moat coverage
Shared moat types
Lifco AB (publ) strengths
Novartis AG strengths
Segment mix
Lifco AB (publ) segments
Full profile >Dental
Oligopoly
Demolition & Tools
Oligopoly
Systems Solutions
Competitive
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.